Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ABEO | PRESS-RELEASE | neutral | 3/10 | Abeona Therapeutics announced it will discuss its fourth quarter and full year 2025 financial results on March 17, 2026, | Mar 3, 2026 |
| PASG | PRESS-RELEASE | neutral | 4/10 | Passage Bio reported Q4 and full-year 2025 financial results, highlighting clinical progress in its upliFT-D trial for f | Mar 3, 2026 |
| TNXP | PRESS-RELEASE | neutral | 4/10 | Tonix Pharmaceuticals has been approved to uplist its common stock from the Nasdaq Capital Market to the Nasdaq Global S | Mar 3, 2026 |
| ESPR | PRESS-RELEASE | bullish | 8/10 | Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the first FDA-approved nasal | Mar 3, 2026 |
| MAIA | PRESS-RELEASE | bearish | 6/10 | MAIA Biotechnology announced the pricing of a $30 million underwritten public offering of 20 million shares at $1.50 per | Mar 2, 2026 |
| MAIA | PRESS-RELEASE | bearish | 6/10 | MAIA Biotechnology has announced an underwritten public offering of common stock and pre-funded warrants, with proceeds | Mar 2, 2026 |
| IVVD | PRESS-RELEASE | neutral | 3/10 | Invivyd announced it will host a conference call on March 5, 2026, to discuss its Q4 and full-year 2025 financial result | Mar 2, 2026 |
| SLDB | PRESS-RELEASE | neutral | 3/10 | Solid Biosciences granted 17,600 restricted stock units (RSUs) to a newly hired employee as an inducement for joining th | Mar 2, 2026 |
| HROW | PRESS-RELEASE | bullish | 8/10 | Harrow reported strong fourth-quarter and full-year 2025 results with record revenue of $89.1 million (up 33% YoY) and f | Mar 2, 2026 |
| CHRS | PRESS-RELEASE | neutral | 3/10 | Coherus Oncology announced it will release its full-year and fourth-quarter 2025 financial results on March 9, 2026, fol | Mar 2, 2026 |
| AIM | PRESS-RELEASE | mixed | 6/10 | AIM ImmunoTech announced an agreement with Thermo Fisher Scientific's PPD clinical research unit to design a Phase 3 tri | Mar 2, 2026 |
| ALLO | PRESS-RELEASE | neutral | 3/10 | Allogene Therapeutics announced it will report its fourth quarter and full year 2025 financial results on March 12, 2026 | Mar 2, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics announced the issuance of a new U.S. patent (No. 12,544,407 B2) for its fibroblast cell therapy targeting | Mar 2, 2026 |
| URGN | PRESS-RELEASE | mixed | 6/10 | UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the | Mar 2, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion announced it will release its full-year 2025 financial results and provide a business update on March 5, 2026, f | Mar 2, 2026 |
| URGN | PRESS-RELEASE | bullish | 7/10 | UroGen Pharma refinanced its debt with Pharmakon Advisors, securing a $200 million initial tranche of a $250 million sen | Mar 2, 2026 |
| ZVRA | PRESS-RELEASE | neutral | 3/10 | Zevra Therapeutics announced it will report its fourth quarter and full-year 2025 financial results on March 9, 2026, af | Mar 2, 2026 |
| BCAB | PRESS-RELEASE | bearish | 7/10 | BioAtla announced a strategic review to explore asset sales, partnerships, or other transactions to maximize shareholder | Mar 2, 2026 |
| PVLA | PRESS-RELEASE | neutral | 5/10 | Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 mil | Mar 2, 2026 |
| DYN | PRESS-RELEASE | bullish | 8/10 | Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscul | Mar 2, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia Therapeutics announced that the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE trial for nexiguran z | Mar 2, 2026 |
| CGTX | PRESS-RELEASE | bullish | 8/10 | Cognition Therapeutics (CGTX) announced plans to advance zervimesine into a registrational development path for dementia | Mar 2, 2026 |
| ETON | PRESS-RELEASE | bullish | 7/10 | Eton Pharmaceuticals has in-licensed U.S. commercialization rights to HEMANGEOL®, the only FDA-approved treatment for in | Mar 2, 2026 |
| ATHE | PRESS-RELEASE | bullish | 8/10 | Alterity Therapeutics highlighted positive Phase 2 clinical data for its lead candidate ATH434 in Multiple System Atroph | Mar 2, 2026 |
| QURE | PRESS-RELEASE | mixed | 6/10 | uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0 | Mar 2, 2026 |
| OCGN | PRESS-RELEASE | bullish | 8/10 | Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therapy OCU400 in retiniti | Mar 2, 2026 |
| APGE | PRESS-RELEASE | neutral | 5/10 | Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net lo | Mar 2, 2026 |
| SION | PRESS-RELEASE | neutral | 4/10 | Sionna Therapeutics reported financial results for Q4 and full year 2025, highlighting increased R&D and G&A spending, a | Mar 2, 2026 |
| GTBP | PRESS-RELEASE | mixed | 5/10 | GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss | Mar 2, 2026 |
| RPRX | PRESS-RELEASE | neutral | 3/10 | Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. S | Mar 2, 2026 |